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Introduction
The incidence of cancer during pregnancy is estimated
to be 0.05-0.1 %. [1] The most common malignancies, in
order of frequency, are breast cancer, leukemia, lym-
phomas, melanoma, gynaecologic cancers as ovarian can-
cer and cervical carcinoma, and bone tumours. The
diagnosis of ovarian cysts or masses since the introduction
of routine obstetric ultrasound examination has become
more frequent than before [2]. The vast majority of these
adnexal masses are benign. The malignancy rate is about
1-6% [3]. During pregnancy, adnexal masses should be ac-
curately evaluated to identify the patients who need surgery
from those who need a ‘wait-and-see’ strategy [2]. The
treatment of ovarian cancer are not well defined because in
literature scientific evidence is limited, so the management
during pregnancy should be discussed in each patient and
a multidisciplinary approach is necessary [4, 5]. 
Case Report
The authors report a case of 36-year-old woman (gravida 2, para
2, two vaginal deliveries) referred to the Gynecologic Department
with diagnosis of endometrioid ovarian adenocarcinoma. Her last
delivery was two month ago. Before pregnancy, in first and sec-
ond trimester of pregnancy ultrasounds were negative. During the
third trimester, an ultrasound showed a multilocular right ovar-
ian cyst that was 15 cm in diameter. She had a vaginal delivery
without complications. One month after delivery, she was hospi-
talized for a surgical operation. She underwent laparoscopy with
right salpingo-oophorectomy, peritoneal biopsies, omentectomy,
and appendectomy. Histopathology revealed endometrioid ade-
nocarcinoma of the right ovary. Omentum, appendix, and peri-
toneal tissue were free of tumor. After diagnosis, the patient ar-
rived at the Gynecological Outpatient Clinic. She had familiarity
for breast cancer: her maternal grandmother had  breast cancer in
pre-menopausal age. In the present department, she had been sub-
jected to a genetic counseling and BRCA1-2 genetic testing,
which showed a negative BRCA1-2 mutation. Total body com-
puted tomography highlighted two small pulmonary nodules,
which were PET-negative. Neoplastic markers (CEA, CA 15.3,
CA125, CA19,9, BhCG and alpha-fetoprotein) were negative.
The patient underwent laparotomic surgery with left salpingo-
oophorectomy, total hysterectomy, pelvic and para-aortic lym-
phadenectomy, and peritoneal washing for optimal surgery
staging. No ascites or residual tumour in the abdominal cavity
were found macroscopically. Histopathology was negative for
residual ovarian cancer. The patient is now being followed by the
oncology department with no evidence of disease.
Discussion
Most of the diagnosis of adnexal masses in pregnancy is
an incidental finding of routine ultrasound during the first
trimester and the incidence rate decreases with increasing
gestational age (1
st
trimester 21.4-75.7%), 2
nd
trimester
10.9-44.4%, 3
rd
trimester 4-22%, postpartum 0-7.1%) [6-
8]. About 90% of such lesions revealed during the first
trimester will disappear spontaneously; the risk of malig-
nancy for the ovarian masses is only 2-5% [3, 4]. Fre-
quently pregnancy-associated ovarian masses are benign or
functional cysts as corpus luteum, theca lutein cyst or en-
dometroid cysts [8]. Most of these can resolve after the first
14-16 weeks of gestation but some, like the theca lutein
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Summary
The prevalence of adnexal masses pregnancy is about 0.19-8.8%. The malignancy rate is around 1-6%, and indeed most cases are be-
nign masses. During pregnancy adnexal masses should be accurately evaluated to identify the patients who need surgery from those who
need a ‘wait-and-see’ strategy. The authors report a case of 36-year-old woman (gravida 2, para 2, two vaginal deliveries) referred to
the Gynecologic Department with diagnosis of endometrioid ovarian adenocarcinoma. The patient underwent laparotomic surgery with
left salpingo-oophorectomy, total hysterectomy, pelvic and para-aortic lymphadenectomy, and peritoneal washing for optimal surgery
staging. No ascites or residual tumour in the abdominal cavity were found macroscopically. Histopathology was negative for residual
ovarian cancer. Currently the treatment and the management of ovarian cancer are not well established because scientific evidence is
limited.
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cysts, can remain after delivery. The more considerable el-
ements for persistence are largest diameter of 5 cm and the
morphostructural features of mass. Also with advancing
pregnancy, the persistence of a lesions, associated with the
increase in size of the uterus, can lead to mass incarceration
with impossibility of a correct positioning of the presenting
fetal part [8]. Furthermore endometriomas can appear dif-
ferent during pregnancy because of decidualized walls cor-
related to high levels of progesterone [4]. Conversely
during pregnancy, the incidence of ovarian cancer is
1:10,000 and 1:50,000 pregnancies and the frequency of
epithelial ovarian cancer (EOC) is about 1:1,000 live births
[4 ,5]. Borderline ovarian cancer are estimated to be around
over 50% of malignant tumors [8, 9]. Before the introduc-
tion of obstetrical ultrasound or MRI into clinical practice,
the adnexal masses during pregnancy were mainly diag-
nosed by physical examination when women presented ab-
dominal/pelvic pains or in presence of a palpable mass [3].
However during pregnancy, the majority of patients pre-
sented unspecific symptoms that were common in normal
pregnant patients, such as abdominal distension or pain,
urinary frequency, and food intolerance. Furthermore the
increase of tumour markers are often associated with the
normal physiologic changes in pregnancy and in presence
of obstetric complications as preeclampsia or HELLP [2].
Clinical approach must aim at the evaluation of the mass
characteristics, the risk of malignancy, and possible com-
plications [8]. Ultrasonography is considered to be the first
choice diagnostic tool in order to identify and to differen-
tiate between benign and malignant masses or to stratify
the risk of malignancy using elements such as tumour size,
morphology and color Doppler. The International Ovarian
Tumor Analysis (IOTA) studies are determined to develop
rules and models to characterize ovarian pathology. Also
several studies show that the ultrasonographic findings of
the adnexal masses can be useful to establish which women
have an increased risk for malignancy versus those who can
be followed up expectantly [2, 10, 11]. Other elements that
guide to a malignant mass include a growth rate greater
than 0.35 cm/week [8]. The most common features associ-
ated with an increased risk for malignancy are the presence
of solid and multiloculated areas, internal septa, papillary
projections, bilateral masses, exuberant blood flow, and as-
cites. However, after 20 weeks of gestation with the in-
creased size of uterus, the diagnostic capability of
ultrasound evaluation is reduced [2, 8]. In presence of sus-
picion of a malignant mass, an abdominal ultrasound may
additionally help to identify metastatic lesions; in case of
diagnostic and clinical uncertainty, MRI can be safely be
used in addition after 12 weeks of gestation [4]. MRI is es-
pecially useful in cases of malignant tumor for evaluation
of retroperitoneum, lymph nodes and abdominal cavity [8].
A CT scan should be utilized after 15 weeks of gestation in
selected patients considering potential risks of fetal irradi-
ation and benefits. PET-TC is not recommended [4,8].
Tumor markers as CA 125, CEA, CA 19.9, LDH, HE4,
alpha-fetoprotein, and BhCG should be used with caution
during pregnancy, because they can be physiologically al-
tered in some stages of pregnancy or in presence of fetal
and placental anomalies [8]. CA 125 is produced by de-
cidua and amnion cells and it is can be physiologically in-
creased during the first trimester of pregnancy up to 65
U/ml; it typically returns to normal values within or after 15
weeks of gestation [2]. This tumor marker is not really help-
ful during pregnancy, but serial measurements can be use-
ful postoperative follow-up. The scientific evidence
regarding a definite management of ovarian cancer in preg-
nancy are limited to small case reports or case series; for
this reason it has not yet been established. The diagnosis
and treatment strategies are not well established, but ma-
ternal and fetal outcome need to be respected.The key fac-
tors to define an individual treatment strategy for each case
include gestational age at diagnosis, FIGO stage, patient’s
preferences, and the possibility of initial surgical procedure
[3, 4]. Considering the possible consequences to the health
of mother and fetus, three main options should be analyzed.
The first approach is to wait for the end of pregnancy and
then begin a standard treatment. A second scenario is to
wait for the surgical investigation until complete fetal ma-
turity of lung. The third approach is to begin neoadjuvant
chemotherapy during pregnancy, until fetal lung maturity is
reached. Few studies have reported the use of platinum/pa-
clitaxel chemotherapy in advanced ovarian cancer and
these suggested no toxicity and physiological growth and
development of the infants [5]. Although knowledge about
the toxicity of chemotherapy during pregnancy is limited,
platinum and taxanes seem safe if they are given after 14
weeks of gestation [3]. In the literature, the safety of surgi-
cal practices ad general procedures during pregnancy are
confirmed. Already in 1963 Munndell had proposed the im-
portance of removing an ovarian mass during pregnancy
on the basis of three indications: elimination of a potential
cause of dystocia, risk of torsion, rupture, or hemorrhage,
and danger of malignancy [3]. The surgery for staging ovar-
ian cancer involves a bilateral salpingo-oophorectomy, total
hysterectomy, pelvic and para-aortic lymphadenectomy,
and omentectomy. Several studies suggested that the pri-
mary surgery at diagnosis includes an ovarian cystectomy,
unilateral salpingo-oophorectomy (USO) only, USO plus
multiple biopsies, or more radical surgery with USO, in-
fracolic omentectomy, appendectomy, peritoneal biopsies,
and even pelvic and para-aortic lymphadenectomy [3].
Treatment should be discussed individually and the clinical
management to decide conservative or radical surgery de-
pends on patient’s age, desire for fertility preservation, and
the extension of tumor. To continue the pregnancy,
chemotherapy is used to prevent the diffusion of malignant
cells and to kill remaining cells. In case of critical medical
conditions, it is necessary to proceed with urgency and in
presence of complications, such as torsion or rupture, emer-
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gency laparoscopy or laparotomy is indicated. During the
management of patients with pelvic mass in pregnancy, and
above all in the case of suspected malignancy, a general as-
sessment of maternal-fetal health and of birth timing is rec-
ommended, while considering short- and long-term
complications of prematurity, before establishing the ges-
tational age for delivery [3].
Conclusion 
During pregnancy the diagnosis of adnexal mass has be-
come more common after the introduction of routine ob-
stetrical ultrasound. For this reason the evaluation of the
ovaries, mostly in the first trimester, should be part of preg-
nancy ultrasound protocols in order to achieve early diag-
nosis of ovarian cancer and to improve the clinical
approach of ovarian tumors. In literature, scientific evi-
dence on the clinical management and the course of treat-
ment of ovarian malignancies in pregnancy is limited,
based on few case reports or retrospective series and they
are not well defined. The decision-making process, includ-
ing chemotherapeutic and surgical options, to establish the
best strategy should be discussed in each individual case.
According to the tumour diameter, gestational age and sur-
gical expertise open surgery and laparoscopy can be con-
sidered. Chemotherapy with platinum/taxanes could be safe
after 14 weeks of gestation. In conclusion, in the presence
of a pelvic mass in pregnancy, and especially in case of sus-
picion of malignancy, a multi-disciplinary team discussion
and specific approach for each patient are recommended
for better clinical management.
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